Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Clements

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
The Journal of Rheumatology|April 17, 2017
Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life StudyShadi Gholizadeh, Sarah D Mills, Rina S Fox, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life StudyRina S Fox, Sarah D Mills, Shadi Gholizadeh, et al.
Clinical and Experimental Rheumatology|June 26, 2010
Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trialsDinesh Khanna, Kevin K Brown, Philip J Clements, et al.
Arthritis and Rheumatism|August 29, 2009
Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract InstrumentDinesh Khanna, Ron D Hays, Paul Maranian, et al.
Rheumatology (Oxford, England)|October 5, 2010
Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trialsMahsa Nashid, Puja P Khanna, Daniel E Furst, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Arthritis and Rheumatism|May 7, 2011
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung diseaseMichael D Roth, Chi-Hong Tseng, Philip J Clements, et al.
Arthritis and Rheumatism|May 28, 2011
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo GroupDinesh Khanna, Chi-Hong Tseng, Niloofar Farmani, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
The Journal of Rheumatology|April 17, 2017
Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life StudyShadi Gholizadeh, Sarah D Mills, Rina S Fox, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life StudyRina S Fox, Sarah D Mills, Shadi Gholizadeh, et al.
Clinical and Experimental Rheumatology|June 26, 2010
Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trialsDinesh Khanna, Kevin K Brown, Philip J Clements, et al.
Arthritis and Rheumatism|August 29, 2009
Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract InstrumentDinesh Khanna, Ron D Hays, Paul Maranian, et al.
Rheumatology (Oxford, England)|October 5, 2010
Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trialsMahsa Nashid, Puja P Khanna, Daniel E Furst, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Arthritis and Rheumatism|May 7, 2011
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung diseaseMichael D Roth, Chi-Hong Tseng, Philip J Clements, et al.
Arthritis and Rheumatism|May 28, 2011
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo GroupDinesh Khanna, Chi-Hong Tseng, Niloofar Farmani, et al.
Pageof 10